Abstract
Growth retardation is a major unsolved problem in children with chronic renal failure. A stimulatory effect of D, on growth rate in EU has been demonstrated (Mehls et al. Am.J.Clin.Nutr.,1978),but clinical results are conflicting. Chesney et al.(New Eng.J.Med.,1978)reported increased growth velocity in uremic children treated by 1.25 (OH)2D3 who had failed to respond to high dosage D3.The present study was designed to compare the efficacy of D3 and 1.25(OH)2D3 (application i.p.;3-point dose response curve) on growth in rats with EU. Methods: 90g Sprague-Dawley rats with stable uremia(2-stage subtotal nephrectomy) of 2 weeks' duration(CCR 18% of normal). All animals fed ad lib. Five groups: I: NX solvent; II and III: NX+D3 (0.5 and 1.0 μg/70g/day); IV and V: NX+1,25 (OH)2 D3 ( 0.625 and 1.25 ng/70g/day). Results: Serum Ca increased (p<0.01) to the same extend in NX+D3 and NX+1.25(OH)2D3. Compared to NX solvent animals (5.9 ±0.2cm/14 days;21±5g/14 days,n=14), the growth rate was significantly better in NX+D3 (6.4±0.3cm/14 days;31±6g/14 days;n=12) and in NX+1.25(OH)2D3 (6.6±0.3cm/14 days; 32±6 g/14 days;n=12). The difference between NX+D3 and NX+1.25(OH)2D3 was not significant. Conclusion: The present study can not confirm that 1.25 (OH)2D3 has a more beneficial effect on growth in uremia than D3.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
